Trials / Completed
CompletedNCT02279823
A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia
A Phase 2, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Solution 5%, Minoxidil Solution 5%, and Vehicle Solution, Applied Twice-daily for 26 Weeks in Males With Androgenetic Alopecia (AGA)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 95 (actual)
- Sponsor
- Intrepid Therapeutics, Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
In this proof-of-concept study, the safety and efficacy of a solution formulation will be investigated in male subjects with androgenetic alopecia (AGA) after twice daily application for up to 26 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CB-03-01 solution | Investigational drug solution |
| DRUG | Minoxidil Solution 5% | FDA approved marketed product |
| DRUG | Placebo solution | Vehicle solution |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2015-12-01
- Completion
- 2016-05-01
- First posted
- 2014-10-31
- Last updated
- 2017-03-13
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02279823. Inclusion in this directory is not an endorsement.